{"id":28793,"date":"2014-08-19T12:06:44","date_gmt":"2014-08-19T16:06:44","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=28793"},"modified":"2014-08-19T12:06:44","modified_gmt":"2014-08-19T16:06:44","slug":"cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793","title":{"rendered":"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/19\/2014 (wallstreetpr) \u2013<strong> CEL-SCI Corporation (NYSEMKT:CVM)<\/strong> said that it was taking ahead its Phase III Immunotherapy Neck and Head Cancer <a href=\"http:\/\/www.digitaljournal.com\/pr\/2130094\" target=\"_blank\">clinical trial<\/a> into Centre Hospitalier Universitaire de Quebec based in Canada. The trial is of the investigational cancer immunotherapy treatment known as Multikine. It is expanding its clinical sites in North America. It wants to accelerate the patient enrollment in Canada.<\/p>\n<p style=\"text-align: justify;\"><strong>The details<\/strong><\/p>\n<p style=\"text-align: justify;\">The Investigator for the Phase III trial is Dr. Andr\u00e9 Fortin. He will look after the investigation at CHUQ. He will monitor the research protocols of radiation therapy CHUQ. He has got extensive expertise and years of experience in treating cancers by the use of radiation therapy. He has treated various forms of cancers including head, neck, digestive and pulmonary cancers. He is an important part in clinical research within the oncology department.<\/p>\n<p style=\"text-align: justify;\"><strong>The Phase III study <\/strong><\/p>\n<p style=\"text-align: justify;\">A Phase III study in respect of Multikine treatment is related with the head and neck cancer treatment. It enrolls only those patients who have advanced primary, but not yet treated form of head and neck cancer. The Phase III study is meant to show a statistically visible improvement in overall survival of patients who enrolled for Multikine treatment regimen, as well as Standard of Care vs. subjects, but treated with SOC only.. The treatment is meant to develop an anti-tumor immune response. The treatment will minimize the chances of the recurrence of the local or regional tumor. If the recurrence rate is reduced, it will enhance the survival rate of the patients who are victim of the neck and head cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>The objective<\/strong><\/p>\n<p style=\"text-align: justify;\">CEL-SCI Corporation (NYSEMKT:CVM) is adding up centers for Phase III trial in Canada and the US. It is the world\u2019s largest clinical trial for head and neck cancer treatment. CEL-SCI Corporation wants to achieve the global enrollment target of around 880 patients by the end of year 2015.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 CEL-SCI Corporation (NYSEMKT:CVM) said that it was taking ahead its Phase III Immunotherapy Neck and Head Cancer clinical trial into [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":28797,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[8121,8114,4556,4557],"stock_ticker":[],"class_list":["post-28793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-andre-fortin","tag-cel-sci-corporation","tag-cel-sci-corporation-nysemktcvm","tag-nysemktcvm","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 CEL-SCI Corporation (NYSEMKT:CVM) said that it was taking ahead its Phase III Immunotherapy Neck and Head Cancer clinical trial into [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-19T16:06:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"274\" \/>\n\t<meta property=\"og:image:height\" content=\"98\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fiona Gibson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fiona Gibson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793\"},\"author\":{\"name\":\"Fiona Gibson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\"},\"headline\":\"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial\",\"datePublished\":\"2014-08-19T16:06:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793\"},\"wordCount\":328,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg\",\"keywords\":[\"Andr\u00e9 Fortin\",\"CEL-SCI Corporation\",\"CEL-SCI Corporation (NYSEMKT:CVM)\",\"NYSEMKT:CVM\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793\",\"name\":\"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg\",\"datePublished\":\"2014-08-19T16:06:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg\",\"width\":274,\"height\":98},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\",\"name\":\"Fiona Gibson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"caption\":\"Fiona Gibson\"},\"description\":\"Fiona is a finance graduate and an expert in analyzing market trends.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\",\"https:\/\/x.com\/@fionahime\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793","og_locale":"en_US","og_type":"article","og_title":"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial - Wall Street PR","og_description":"Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 CEL-SCI Corporation (NYSEMKT:CVM) said that it was taking ahead its Phase III Immunotherapy Neck and Head Cancer clinical trial into [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-19T16:06:44+00:00","og_image":[{"width":274,"height":98,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg","type":"image\/jpeg"}],"author":"Fiona Gibson","twitter_misc":{"Written by":"Fiona Gibson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793"},"author":{"name":"Fiona Gibson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e"},"headline":"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial","datePublished":"2014-08-19T16:06:44+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793"},"wordCount":328,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg","keywords":["Andr\u00e9 Fortin","CEL-SCI Corporation","CEL-SCI Corporation (NYSEMKT:CVM)","NYSEMKT:CVM"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793","url":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793","name":"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg","datePublished":"2014-08-19T16:06:44+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/cel.jpg","width":274,"height":98},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cel-sci-corporation-nysemktcvm-moves-ahead-with-phase-iii-immunotherapy-head-and-neck-cancer-trial-28793#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"CEL-SCI Corporation (NYSEMKT:CVM) Moves Ahead With Phase III Immunotherapy Head and Neck Cancer Trial"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e","name":"Fiona Gibson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","caption":"Fiona Gibson"},"description":"Fiona is a finance graduate and an expert in analyzing market trends.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr","https:\/\/x.com\/@fionahime"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=28793"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28793\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/28797"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=28793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=28793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=28793"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=28793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}